https://www.selleckchem.com/sc....reening/chemical-lib
Background We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose of SCIg in MG and whether measured immunoglobulin G (IgG) levels correlated with measures of disease burden were not reported. Objectives To understand the relationship between SCIg dosing and serum IgG levels on measures of disease burden quantitative MG (QMG), MG activities of daily living (MG-ADL), MG composite (MGC), and manual muscle testing
Like
Comment
Share
